已收录 268921 条政策
 政策提纲
  • 暂无提纲
Triweekly administration of parathyroid hormone (1–34) accelerates bone healing in a rat refractory fracture model
[摘要] BackgroundSome reports have shown that intermittent parathyroid hormone (PTH) (1–34) treatment for patients with delayed union or nonunion have led to successful healing. In this study, we investigated whether systemic intermittent administration of PTH (1–34) has a beneficial effect on bone healing in a rat refractory fracture model.MethodsWe created a refractory femoral fracture model in 32 rats with periosteal cauterization that leads to atrophic nonunion at 8 weeks after surgery. Half the rats received subcutaneous intermittent human PTH (1–34) injections at a dosage of 100 μg/kg, thrice a week for 8 weeks. The other half received the vehicle only. At 8 weeks after fracture, radiographic, histological and mechanical assessments were performed.ResultsRadiographic assessments showed that the union rate was significantly higher in the PTH group than in the control group (P < 0.05). The degree of fracture repair as scored using the Allen grading system in histological assessment was significantly greater in the PTH group than in the control group (P < 0.05). The ultimate stress and stiffness measurements were significantly greater in the PTH group than in the control group (p < 0.05).ConclusionsWe demonstrated that triweekly administration of PTH (1–34) increased union rate and accelerated bone healing in a rat refractory fracture model, suggesting that systemic administration of PTH (1–34) could become a novel and useful therapy for accelerating fracture healing in patients at high risk of delayed union or nonunion.
[发布日期] 2017-12-21 [发布机构] 
[效力级别]  [学科分类] 
[关键词] Parathyroid hormone (1–34);Teriparatide;Fracture healing;Delayed union;Nonunion [时效性] 
   浏览次数:3      统一登录查看全文      激活码登录查看全文